|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
CN100391445C
(zh)
|
1996-01-24 |
2008-06-04 |
美国政府陆军部 |
新型的“非突发的”持续释放聚(丙交酯/乙交酯)的微球
|
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
DE3673317D1
(de)
|
1985-10-11 |
1990-09-13 |
Duphar Int Res |
Automatische spritze.
|
|
GB2209937B
(en)
|
1987-09-21 |
1991-07-03 |
Depiopharm S A |
Water insoluble polypeptides
|
|
US5981485A
(en)
|
1997-07-14 |
1999-11-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
HU221294B1
(en)
|
1989-07-07 |
2002-09-28 |
Novartis Ag |
Process for producing retarde compositions containing the active ingredient in a polymeric carrier
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5668117A
(en)
|
1991-02-22 |
1997-09-16 |
Shapiro; Howard K. |
Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5578442A
(en)
|
1992-03-23 |
1996-11-26 |
Vivorx, Inc. |
Graft copolymers of polycationic species and water-soluble polymers, and use therefor
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US5643605A
(en)
|
1993-10-25 |
1997-07-01 |
Genentech, Inc. |
Methods and compositions for microencapsulation of adjuvants
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5858964A
(en)
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
|
IT1276690B1
(it)
|
1995-06-09 |
1997-11-03 |
Ira Srl |
Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
|
|
HU230048B1
(hu)
|
1996-02-09 |
2015-06-29 |
Abbvie Biotechnology Ltd |
Humán TNFalfa-kötő antitestek alkalmazása
|
|
US5792477A
(en)
|
1996-05-07 |
1998-08-11 |
Alkermes Controlled Therapeutics, Inc. Ii |
Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
|
|
US20070185032A1
(en)
|
1996-12-11 |
2007-08-09 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
US5945126A
(en)
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
|
AR012448A1
(es)
|
1997-04-18 |
2000-10-18 |
Ipsen Pharma Biotech |
Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
|
|
US6454746B1
(en)
|
1997-06-04 |
2002-09-24 |
Eli Lilly And Company |
Medication delivery apparatus
|
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
|
AU2868699A
(en)
|
1998-02-13 |
1999-08-30 |
Autoimmune, Inc. |
Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
|
|
JP2003521448A
(ja)
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
EP2090583B1
(en)
|
1998-09-25 |
2011-07-13 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
AU6281599A
(en)
|
1998-10-02 |
2000-04-26 |
Yeda Research And Development Co. Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
AU775073C
(en)
|
1998-11-12 |
2007-05-03 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
|
|
US6194006B1
(en)
|
1998-12-30 |
2001-02-27 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of microparticles having a selected release profile
|
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
|
US6872739B1
(en)
|
1999-06-04 |
2005-03-29 |
Vereniging Voor Christelijk Wetenshappelikjk Onderwijs |
Use of riluzole for the treatment of multiple sclerosis
|
|
US6531130B1
(en)
|
1999-07-06 |
2003-03-11 |
The Board Of Trustees Of The Leland Stanford University |
Treatment of demyelinating autoimmune disease with ordered peptides
|
|
EP1248643B1
(en)
|
2000-01-20 |
2005-08-17 |
YEDA RESEARCH AND DEVELOPMENT Co. LTD. |
The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
|
|
JP2003522799A
(ja)
|
2000-02-18 |
2003-07-29 |
イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス |
コポリマー1の経口、経鼻および経肺投与製剤
|
|
ZA200206457B
(en)
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
PL363431A1
(en)
|
2000-06-05 |
2004-11-15 |
Teva Pharmaceuticals Industries, Ltd. |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
DE60116467T2
(de)
|
2000-06-07 |
2006-11-02 |
Yeda Research And Development Co., Ltd. |
Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
KR100392501B1
(ko)
|
2000-06-28 |
2003-07-22 |
동국제약 주식회사 |
다중 에멀젼법에 의한 서방출성 미립구의 제조방법
|
|
WO2008150547A1
(en)
|
2007-06-04 |
2008-12-11 |
The Regents Of The University Of California |
Pregnancy hormone combination for treatment of autoimmune diseases
|
|
US6835711B2
(en)
|
2001-06-28 |
2004-12-28 |
Yeda Research And Development Co. Ltd. |
Use of poly-Glu,Tyr for neuroprotective therapy
|
|
AU2002320360B2
(en)
|
2001-07-10 |
2005-05-26 |
Teva Pharmaceutical Industries Ltd. |
Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
|
|
JP5010798B2
(ja)
|
2001-10-03 |
2012-08-29 |
プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
自己免疫疾患を抑制するためのコポリマー、及びその使用方法
|
|
ES2367422T3
(es)
|
2001-10-09 |
2011-11-03 |
Amgen Inc. |
Derivados de imidazol como agentes antiinflamatorios.
|
|
WO2003048207A2
(en)
|
2001-11-28 |
2003-06-12 |
Immunomedics, Inc. |
Anti-dota antibody
|
|
CA2469393C
(en)
|
2001-12-04 |
2010-05-25 |
Teva Pharmaceutical Industries, Ltd. |
Processes for the measurement of the potency of glatiramer acetate
|
|
US7351686B2
(en)
|
2001-12-06 |
2008-04-01 |
Yeda Research And Development Co. Ltd. |
Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
|
|
US8871241B2
(en)
|
2002-05-07 |
2014-10-28 |
Psivida Us, Inc. |
Injectable sustained release delivery devices
|
|
CN1398584A
(zh)
|
2002-07-15 |
2003-02-26 |
裴福兴 |
一种bFGF-PLGA缓释微球及其制备方法和用途
|
|
DE10237146A1
(de)
|
2002-08-13 |
2004-03-04 |
Medac Gesellschaft für klinische Spezialpräparate mbH |
Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
|
|
AU2003270701B2
(en)
|
2002-10-31 |
2009-11-12 |
Amgen Inc. |
Antiinflammation agents
|
|
EP1565486A2
(en)
|
2002-11-13 |
2005-08-24 |
Apotex Pharmachem Inc. |
Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
|
|
CN100464796C
(zh)
|
2002-11-25 |
2009-03-04 |
特克法马许可公司 |
包括可复位安全释放设备的自动注射器
|
|
WO2004060265A2
(en)
|
2003-01-07 |
2004-07-22 |
Yeda Research And Development Co. Ltd. |
Eye-drop vaccine containing copolymer 1 for therapeutic immunization
|
|
NZ569331A
(en)
|
2003-01-21 |
2010-08-27 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
|
EP1603530A1
(en)
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
HRP20140524T1
(hr)
|
2003-05-14 |
2014-12-19 |
Teva Pharmaceutical Industries Ltd. |
Kombinacijska terapija glatiramer acetatom i mitoksantronom za lijeäśenje multiple skleroze
|
|
WO2005035088A2
(en)
|
2003-07-18 |
2005-04-21 |
Baxter International, Inc. |
Method for preparing small spherical by controlled phase separation
|
|
US20050142205A1
(en)
|
2003-07-18 |
2005-06-30 |
Julia Rashba-Step |
Methods for encapsulating small spherical particles prepared by controlled phase separation
|
|
US20060276390A1
(en)
|
2003-07-31 |
2006-12-07 |
Yeda Research And Development Co. Ltd. |
Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
|
|
US20050170004A1
(en)
|
2003-10-31 |
2005-08-04 |
Vered Rosenberger |
Nanoparticles for drug delivery
|
|
EP1684797A1
(en)
|
2003-11-12 |
2006-08-02 |
Yeda Research and Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
CA2553254C
(en)
|
2004-01-12 |
2013-12-17 |
The Trustees Of The University Of Pennsylvania |
Long-term delivery formulations and methods of use thereof
|
|
RU2006134701A
(ru)
|
2004-03-01 |
2008-04-10 |
Пептиммьюн |
Способы и композиции для лечения аутоиммунных заболеваний
|
|
CA2558380A1
(en)
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US7576051B2
(en)
|
2004-03-11 |
2009-08-18 |
Sanyo Chemical Industries, Ltd. |
Wound dressing for accelerating epidermal regeneration
|
|
MXPA06011021A
(es)
|
2004-03-25 |
2007-04-13 |
Johnson & Johnson |
Compuestos de imidazol.
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
RU2410115C2
(ru)
|
2004-05-07 |
2011-01-27 |
Пептиммьюн, Инк. |
Способы лечения заболеваний с помощью статистических сополимеров
|
|
EP1753455A2
(en)
|
2004-06-04 |
2007-02-21 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
|
US8053197B2
(en)
|
2004-07-30 |
2011-11-08 |
Oregon Health & Science University |
Methods for detecting and treating autoimmune disorders
|
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
CA2579038A1
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
DK1797109T3
(en)
|
2004-09-09 |
2016-04-11 |
Yeda Res & Dev |
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
|
|
NZ554018A
(en)
|
2004-09-09 |
2009-06-26 |
Teva Pharma |
Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
|
|
WO2006050122A1
(en)
|
2004-10-29 |
2006-05-11 |
Sandoz Ag |
Processes for preparing glatiramer
|
|
JP2008520717A
(ja)
|
2004-11-19 |
2008-06-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症についての処置
|
|
EP1827108B1
(en)
|
2004-11-29 |
2015-04-08 |
Yeda Research And Development Co., Ltd. |
Induction of neurogenesis and stem cell therapy in combination with copolymer 1
|
|
AU2006211101A1
(en)
|
2005-02-02 |
2006-08-10 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
|
|
US20060172942A1
(en)
|
2005-02-02 |
2006-08-03 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
WO2006089066A1
(en)
|
2005-02-15 |
2006-08-24 |
Neuromolecular Pharmaceuticals, Inc. |
Combinations therapy for treatment of demyelinating conditions
|
|
HRP20130622T1
(en)
|
2005-02-17 |
2013-08-31 |
Teva Pharmaceutical Industries Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
EP1891233A4
(en)
|
2005-04-25 |
2010-03-24 |
Yeda Res & Dev |
MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
|
|
KR20080016659A
(ko)
|
2005-05-20 |
2008-02-21 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제의 억제제로서 유용한 피롤로피리딘
|
|
WO2007021970A2
(en)
|
2005-08-15 |
2007-02-22 |
Praecis Pharmaceuticals, Inc. |
Stable pharmaceutical formulations and methods of use thereof
|
|
WO2007030573A2
(en)
|
2005-09-09 |
2007-03-15 |
Yeda Research And Development Co. Ltd. |
Polypeptides useful for molecular weight determinations
|
|
US7517856B2
(en)
|
2005-10-11 |
2009-04-14 |
Ben-Gurion University Of The Negev Research And Development Authority |
Bioconjugates comprising sulfated polysaccharides and their uses
|
|
US20070161566A1
(en)
|
2006-01-11 |
2007-07-12 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
HUE047230T2
(hu)
|
2006-02-28 |
2020-04-28 |
Biogen Ma Inc |
Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
|
|
CA2641160A1
(en)
|
2006-02-28 |
2007-09-07 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
|
CA2680333C
(en)
|
2006-03-15 |
2016-10-25 |
The Brigham And Women's Hospital, Inc. |
Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
|
|
ES2565035T3
(es)
|
2006-04-28 |
2016-03-30 |
Momenta Pharmaceuticals, Inc. |
Métodos para evaluar mezclas de péptidos
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
ES2605154T3
(es)
|
2006-06-28 |
2017-03-13 |
Yeda Research And Development Company Limited |
Copolímero 1 para el tratamiento de la degeneración macular relacionada con la edad
|
|
TWI498137B
(zh)
|
2006-06-30 |
2015-09-01 |
Abbvie Biotechnology Ltd |
自動注射裝置
|
|
ES2338488T3
(es)
|
2006-07-05 |
2010-05-07 |
Momenta Pharmaceuticals, Inc. |
Proceso mejorado para la preparacion de copolimero-1.
|
|
WO2008060786A2
(en)
|
2006-10-06 |
2008-05-22 |
Baxter International Inc. |
Microencapsules containing surface-modified microparticles and methods of forming and using the same
|
|
CN101562977A
(zh)
|
2006-12-15 |
2009-10-21 |
艾博特公司 |
新的二唑化合物
|
|
WO2008075365A1
(en)
|
2006-12-20 |
2008-06-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions and methods for treatment of age related degeneration of the retina
|
|
PT2139467T
(pt)
|
2007-02-08 |
2016-12-16 |
Biogen Ma Inc |
Neuroproteção em doenças desmielinizantes
|
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
PT2187882E
(pt)
|
2007-07-11 |
2013-04-17 |
Medicinova Inc |
Tratamento de uma doença neurodegenerativa progressiva com ibudilast
|
|
US8193147B2
(en)
|
2007-09-24 |
2012-06-05 |
Hadasit Medical Research Services & Development Ltd. |
Use of copolymer 1 for treatment of muscular dystrophy
|
|
MX2010003113A
(es)
|
2007-09-25 |
2010-04-01 |
Abbott Lab |
Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
|
|
WO2009042892A1
(en)
|
2007-09-26 |
2009-04-02 |
Oregon Health & Science University |
Cyclic undecapeptides and derivatives as multiple sclerosis therapies
|
|
WO2009063459A2
(en)
|
2007-11-13 |
2009-05-22 |
Yeda Research And Development Co. Ltd |
Synthetic peptide copolymers for treatment of neurodevelopmental disorders
|
|
CN101877963A
(zh)
|
2007-11-28 |
2010-11-03 |
泰华制药工业有限公司 |
延缓临床确诊的多发性硬化症发作的方法
|
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
|
EP2318012A4
(en)
|
2008-07-25 |
2011-08-24 |
Univ Johns Hopkins |
METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING AUTOMINATION DISEASES
|
|
EP2341904A1
(en)
|
2008-08-26 |
2011-07-13 |
Fibrogen, Inc. |
Methods for treatment of multiple sclerosis
|
|
CL2009001841A1
(es)
|
2008-09-10 |
2011-02-18 |
Acorda Therapeutics Inc |
Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
JP2012505257A
(ja)
|
2008-10-13 |
2012-03-01 |
バイオヴィスタ,インコーポレイテッド |
多発性硬化症治療のための組成物および方法
|
|
AU2009324495B2
(en)
|
2008-12-11 |
2015-12-24 |
Biovista, Inc. |
Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
|
|
BRPI1008602A8
(pt)
|
2009-02-18 |
2018-01-02 |
Eyeon Particle Sciences Llc |
uso de co-polímero bi-funcional para as aplicações oftálmicas e outras aplicações tópicas e locais
|
|
EP2246048A1
(en)
|
2009-04-30 |
2010-11-03 |
Santhera Pharmaceuticals (Schweiz) AG |
Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
|
|
NZ577731A
(en)
|
2009-06-16 |
2010-08-27 |
Innate Therapeutics Ltd |
Compositions and methods for treatment of multiple sclerosis
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
PL2275086T3
(pl)
|
2009-07-15 |
2012-09-28 |
Teva Pharma |
Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania
|
|
AU2013203367C1
(en)
|
2009-08-20 |
2018-01-18 |
Yeda Research & Development Co., Ltd |
Low frequency glatiramer acetate therapy
|
|
SG10201405806SA
(en)
|
2009-08-20 |
2014-11-27 |
Yeda Res & Dev |
Low Frequency Glatiramer Acetate Therapy
|
|
ES2664727T3
(es)
|
2009-10-22 |
2018-04-23 |
University College Dublin National University Of Ireland, Dublin |
Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
|
|
ES2699692T3
(es)
*
|
2010-01-04 |
2019-02-12 |
Mapi Pharma Ltd |
Sistema de depósito que comprende acetato de glatiramer
|
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
US20130046015A1
(en)
|
2010-02-11 |
2013-02-21 |
Robert C. Axtell |
Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
|
|
PT2533634E
(pt)
|
2010-02-12 |
2015-12-28 |
Biogen Ma Inc |
Neuroproteção em doenças desmielinizantes
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
EP2529757B1
(en)
*
|
2011-05-31 |
2014-01-08 |
Laboratorios Farmaceuticos Rovi, S.A. |
Paliperidone implant formulation
|
|
AU2011282635B2
(en)
|
2010-07-29 |
2015-05-28 |
Dr. Reddy's Laboratories Ltd. |
Glatiramer acetate molecular weight markers
|
|
EP2605797A2
(en)
*
|
2010-08-20 |
2013-06-26 |
Cerulean Pharma Inc. |
Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
|
|
ES2602977T3
(es)
|
2010-10-11 |
2017-02-23 |
Teva Pharmaceutical Industries Ltd. |
Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
|
|
GB2485169A
(en)
|
2010-11-03 |
2012-05-09 |
Univ Jw Goethe Frankfurt Main |
(R)-flurbiprofen for use in the treatment of multiple sclerosis
|
|
EP2500072A1
(en)
|
2011-03-15 |
2012-09-19 |
LEK Pharmaceuticals d.d. |
A novel process of residual solvent removal
|
|
US20120328567A1
(en)
|
2011-04-08 |
2012-12-27 |
Steven Bushnell |
Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
|
|
US9409987B2
(en)
|
2011-04-15 |
2016-08-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
WO2012143924A1
(en)
|
2011-04-21 |
2012-10-26 |
Mapi Pharma Ltd. |
Random pentapolymer for treatment of autoimmune diseases
|
|
FI3467509T3
(fi)
|
2011-05-04 |
2026-02-11 |
Cellular Tech Ltd |
Cns-antigeenispesifisiä b-solu-, t-solu- ja vasta-ainemäärityksiä ja niiden käyttötapoja multippeliskleroosin diagnosoinnissa ja hoidossa
|
|
WO2012150495A1
(en)
|
2011-05-05 |
2012-11-08 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
|
AU2012323345A1
(en)
|
2011-10-10 |
2014-05-22 |
Teva Pharmaceutical Industries Ltd. |
Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
|
|
WO2013138244A2
(en)
|
2012-03-12 |
2013-09-19 |
Medimmune, Llc |
Treatment of multiple sclerosis with anti-cd19 antibody
|
|
GB201208850D0
(en)
|
2012-05-18 |
2012-07-04 |
Alphaptose Gmbh |
Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
|
|
US9132138B2
(en)
|
2012-08-27 |
2015-09-15 |
Casi Pharmaceuticals, Inc. |
Method for the treatment of multiple sclerosis
|
|
CN104870014A
(zh)
|
2012-10-09 |
2015-08-26 |
比奥根Ma公司 |
联合治疗及用于治疗脱髓鞘病症的用途
|
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
|
EP2941274A4
(en)
|
2013-01-04 |
2016-11-16 |
Teva Pharma |
CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE
|
|
ES2859553T3
(es)
|
2013-01-08 |
2021-10-04 |
Pathologica Llc |
Mitoguazona para el tratamiento de esclerosis múltiple progresiva
|
|
WO2014127139A1
(en)
|
2013-02-15 |
2014-08-21 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with laquinimod
|
|
TW201521757A
(zh)
|
2013-03-12 |
2015-06-16 |
Teva Pharma |
先後通過利妥昔單抗(rituximab)誘導治療及格拉默醋酸鹽(glatiramer acetate)治療
|
|
WO2014145203A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Systems and methods for characterization of multiple sclerosis
|
|
CN103169670B
(zh)
*
|
2013-03-22 |
2016-07-06 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷微球及其制备方法
|
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
|
AU2014319921A1
(en)
|
2013-09-11 |
2016-03-17 |
Compugen Ltd. |
Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US10493122B2
(en)
|
2014-03-17 |
2019-12-03 |
Mapi Pharma Ltd. |
Sublingual delivery of glatiramer acetate
|
|
EP3137087B1
(en)
|
2014-04-28 |
2023-09-06 |
The Regents of the University of California |
Estrogen combination for treatment of multiple sclerosis
|
|
WO2016036721A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Estrogen receptor ligand treatment for neurodegenerative diseases
|
|
WO2016036719A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Estrogen therapy for brain gray matter atrophy and associated disability
|
|
WO2016040861A1
(en)
|
2014-09-12 |
2016-03-17 |
Biogen Ma Inc. |
Systems and methods for characterization of multiple sclerosis
|
|
WO2016064997A1
(en)
|
2014-10-22 |
2016-04-28 |
The Regents Of The University Of California |
Compositions and methods for treating fatigue and depression
|
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
US20160213633A1
(en)
|
2015-01-28 |
2016-07-28 |
Teva Pharmaceutical Industries, Ltd. |
Method of inducing anti-glatiramer acetate antibody response
|
|
WO2016160830A1
(en)
|
2015-03-30 |
2016-10-06 |
The Regents Of The University Of California |
Methods of providing neuroprotective therapy
|
|
EP3277285B1
(en)
|
2015-03-30 |
2024-07-17 |
The Regents of the University of California |
Estriol for reducing cortical gray matter atrophy
|
|
WO2018002930A1
(en)
*
|
2016-06-30 |
2018-01-04 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
|
US11471421B2
(en)
*
|
2016-08-28 |
2022-10-18 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
BR112019017724A2
(pt)
|
2017-03-26 |
2020-03-31 |
Mapi Pharma Ltd. |
Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
|
|
WO2018211486A1
(en)
|
2017-05-15 |
2018-11-22 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
|